OUR HISTORY

1997
Foundation
1997
First EU GMP artesunate: Arinate®
First β-Artemether: Artemether® 80mg/ml
2000
First EU GMP pediatric suspension: Artesiane®
2000
2002
Launch of Arinate®, arthemether IV, Dafazol® & Artesiane® suppogel
2002
2003
First Co-Arinate® co-blister
2003
2004
First artemisinin-based combination therapy paediatric suspension: Co-Artesiane® + Co-Arinate® FDC
2004
2005
Move to our current headquarters in Turnhout
2005
2007
Start portfolio diversification program
2007
2009
Dafra Pharma Swiss subsidiary for warehousing and logistics
2009
2011
100 sales representatives in Africa
2011
2013
Passing away of founder / R&D director / president Dr. Frans Herwig Jansen
2013
2014
Introduction CRM system African sales forces
2014
2017
20 years Dafra Pharma
2017
175 sales representatives in Africa
2018
First RID (Rencontres Internationales Dafra)
2018
2018
Introduction of our online education system: DAM (Dafra Academy Medical) for our African sales forces
2018
2020
Well-balanced product portfolio
2020
2020
Excellence Dafra Togo: eloquence and scientific communication competition
2020
2020
> 200 sales representatives in Africa
2020
2020
First online RID (Rencontres Internationales Dafra)
2020
2021
Introduction CRM 2.0 for our African sales forces
2021
2021
Excellence Dafra Ivory Coast: eloquence and scientific communication competition
2021
2021
Excellence Dafra Togo 2.0: eloquence and scientific communication competition
2021
2021
Excellence Dafra Cameroon: eloquence and scientific communication competition
2021
2021
Excellence Dafra Benin: eloquence and scientific communication competition
2021
2022
25 years Dafra Pharma
2022
2023
Move of warehouse in Swiss to Belgium
2023

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma